Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

JAK2 V617f in chronic myeloid leukemia: driving force or passive bystander?

Hematology (Amsterdam, Netherlands) - 1 Dec 2022

Tarantini Francesco, Cumbo Cosimo, Zagaria Antonella, Parciante Elisa, Anelli Luisa, Coccaro Nicoletta, Tota Giuseppina, Minervini Crescenzio Francesco, Redavid Immacolata, Rossi Antonella Russo, Conserva Maria Rosa, Specchia Giorgina, Musto Pellegrino, Albano Francesco

Abstract excerpt

OBJECTIVES: BCR-ABL1 and JAK2 V617F coexistence in myeloproliferative neoplasms has been described as concomitant or sequential events. Despite this, we present a unique case of chronic myeloid leukemia (CML) not referable to either of the known scenarios. METHODS: BCR-ABL1 molecular monitoring was performed by real-time quantitative PCR (RQ-PCR). At the time of molecular relapse, a targeted next-generation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Fusion Proteins, bcr-abl
Share to Janus Kinase 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Mutation

Share to Myeloproliferative Disorders

Share to Real-Time Polymerase Chain Reaction

Source

Identifiers

PMID: 35938951
DOI: 10.1080/16078454.2022.2108902

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

JAK2 V617f in chronic myeloid leukemia: driving force or passive bystander?PMID 35938951Read ↗

Co-existence of BCR-ABL and JAK2V617F mutation in resistant chronic myeloid leukemia in the imatinib era: Is there a correlation?Semantic proximity Read ↗

Co-occurrence of JAK2-V617 F mutation and BCR::ABL1 translocation in chronic myeloproliferative neoplasms: a potentially confounding genetic combinationSemantic proximity Read ↗

Concurrent JAK2-Positive Myeloproliferative Disorder and Chronic Myelogenous Leukemia: A Novel Entity? A Case Report With Review of the LiteratureSemantic proximity Read ↗

Emergence of Chronic Myelogenous Leukemia From a Background of Myeloproliferative Disorder: JAK2V617F as a Potential Risk Factor for BCR-ABL TranslocationSemantic proximity Read ↗

Clinical and laboratory relevance of JAK2 V617F and BCR-ABL co-existence in Philadelphia positive CML patients.Semantic proximity Read ↗

BCR/ABL-negative chronic myeloproliferative disorders: JAK2 mutation and beyond.Semantic proximity Read ↗

Sequential Development of JAK2V617F Mutation and BCR-ABL1 Fusion in Individual Patients With Myeloproliferative Neoplasms.Semantic proximity Read ↗

[Sequential development of BCR::ABL1-positive chronic myeloid leukemia during treatment of JAK2 V617F-positive essential thrombocythemia].Semantic proximity Read ↗

Mutations and chromosomal rearrangements of JAK2: not only a myeloid issue.Semantic proximity Read ↗

Concurrent JAK2(V617F) mutation and BCR-ABL translocation within committed myeloid progenitors in myelofibrosis.Semantic proximity Read ↗

The concomitant occurrence of JAK2V617F mutation and BCR/ABL transcript with phenotypic expression - an overlapping myeloproliferative disorder or two distinct diseases? - case report.Semantic proximity Read ↗

BCR-ABL1-positive chronic myeloid leukemia emerging in a patient with secondary myelofibrosis harboring the JAK2-V617F mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.